Table 2 Reason for tolvaptan discontinuation (n = 114)
Reason for discontinuation | n (%a) |
|---|---|
Abnormal LFTs | 10 (2.1) |
Acute renal impairment | 1 (0.2) |
Adverse event, NOS | 2 (0.4) |
Aquaretic tolerability | 20 (4.2) |
Disease progression | 7 (1.5) |
HCP/ patient decision, NOS | 28 (5.9) |
Non-hepatic adverse event, NOS | 12 (2.5) |
Treatment break – failed to restart treatment | 11 (2.3) |
Patient lost to follow up | 10 (2.1) |
Other | 13 (2.6) |